Oesophageal cancer
Oesophageal cancer
There are two main types of oesophageal cancer, squamous cell carcinoma (SCC) and adenocarcinoma (ACA). SCC usually affects the middle third of the oesophagus and is associated with smoking, alcohol and low socio-economic status. ACA affects the lower third of the oesophagus and is associated with gastro-oesophageal reflux disease. The UK has the highest incidence of ACA in the world and it is rising. Treatment may be palliative or curative. Curative treatment for advanced disease consists of neo-adjuvant chemotherapy or chemoradiotherapy followed by surgery. In the UK, the most common operation is a two-phase Ivor-Lewis oesophagectomy. Increasingly, surgery is carried out with a minimally invasive approach. Modern management has reduced the morbidity and mortality of the perioperative period but progress in long-term survival has been slow. Enhanced perioperative patient pathways and stratified therapies (according to characteristics of the tumour at the molecular level) offer the promise of further improvements. On-going clinical trials are assessing the role of monoclonal antibodies in the treatment of oesophageal cancer.
Diagnosis, enhanced recovery, epidemiology, immunotherapy, neoadjuvant, oesophageal neoplasms, oesophagectomy, pathology, radiotherapy
627-634
Walker, Robert C.
c8fbfe1c-349d-497f-b24e-0295c84c4634
Underwood, Timothy J.
8e81bf60-edd2-4b0e-8324-3068c95ea1c6
November 2017
Walker, Robert C.
c8fbfe1c-349d-497f-b24e-0295c84c4634
Underwood, Timothy J.
8e81bf60-edd2-4b0e-8324-3068c95ea1c6
Abstract
There are two main types of oesophageal cancer, squamous cell carcinoma (SCC) and adenocarcinoma (ACA). SCC usually affects the middle third of the oesophagus and is associated with smoking, alcohol and low socio-economic status. ACA affects the lower third of the oesophagus and is associated with gastro-oesophageal reflux disease. The UK has the highest incidence of ACA in the world and it is rising. Treatment may be palliative or curative. Curative treatment for advanced disease consists of neo-adjuvant chemotherapy or chemoradiotherapy followed by surgery. In the UK, the most common operation is a two-phase Ivor-Lewis oesophagectomy. Increasingly, surgery is carried out with a minimally invasive approach. Modern management has reduced the morbidity and mortality of the perioperative period but progress in long-term survival has been slow. Enhanced perioperative patient pathways and stratified therapies (according to characteristics of the tumour at the molecular level) offer the promise of further improvements. On-going clinical trials are assessing the role of monoclonal antibodies in the treatment of oesophageal cancer.
Text
Oesophageal Cancer 2017
- Accepted Manuscript
More information
Accepted/In Press date: 15 September 2017
e-pub ahead of print date: 2 November 2017
Published date: November 2017
Keywords:
Diagnosis, enhanced recovery, epidemiology, immunotherapy, neoadjuvant, oesophageal neoplasms, oesophagectomy, pathology, radiotherapy
Identifiers
Local EPrints ID: 416412
URI: http://eprints.soton.ac.uk/id/eprint/416412
ISSN: 0263-9319
PURE UUID: 2bd833c2-081f-4a19-8408-de6a6be1ff89
Catalogue record
Date deposited: 15 Dec 2017 17:30
Last modified: 16 Mar 2024 06:01
Export record
Altmetrics
Contributors
Author:
Robert C. Walker
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics